Clinical trials: HPV Vaccinations
HPV Vaccine, HPV
Adaptation Of An HPV Education Resource To Promote HPV Vaccination
The purpose of the study is to assess Human Papillomavirus (HPV) and HPV vaccination knowledge, awareness, attitudes, health beliefs, and behaviors as well as educational preferences for learning more about HPV and HPV…
- Trial name
- NCT04974619
- Testing
- Online survey, Focus groups or Individual Interviews, Interviews
- Where
- 2 sites in United States, Puerto Rico
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Cervical Cancer
The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer
A Multi-Center, Open-label Phase Ib-II Trial of the Combination of GX-188E Vaccination and Pembrolizumab in Patients with Advanced, Non-Resectable HPV-Positive Cervical Cancer
- Trial name
- NCT03444376
- Testing
- GX-188E, KEYTRUDA®
- Where
- 9 sites in South Korea
- Volunteers
- 65 people
- Sponsor
- Genexine, Inc.
Human Papillomavirus
Long Term Immune Memory Responses to HPV Vaccination Following 2 vs 3 Doses of Quad-HPV Vaccine
The overall aim of this study is to further understand the memory response to HPV vaccination in subjects who have received 2 versus 3 doses of quadrivalent HPV vaccine.
- Trial name
- Merck08 (NCT02968420)
- Testing
- Human Papillomavirus 9-valent Vaccine, Recombinant
- Where
- Canada
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Human Papillomavirus
Prevalence of Genital HPV Infection in Males Following Introduction of Universal Male HPV Vaccination
This study will examine how common HPV infection is in teenage males in Australia before and after the introduction of universal school based vaccination of males in Australia.
- Trial name
- Impress (NCT02003508)
- Where
- Australia
- Volunteers
- 345 people, healthy volunteers welcome
- Sponsor
- The Alfred
GARDASIL Vaccination
Innovative Tool to Increase Completion of Human Papillomavirus (HPV) Vaccine Series
Planned Parenthood Federation of America's (PPFA) Medical Affairs Division will conduct a prospective, cluster randomized trial to determine which factors influence the acquisition of the second and third human papillomavirus…
- Trial name
- NCT01343485
- Testing
- Computer reminder system
- Where
- 9 sites in United States
- Volunteers
- 365 people, healthy volunteers welcome
- Sponsor
- Planned Parenthood Federation of America
Vaccine Hesitancy
Increasing Vaccine Uptake Among Adolescents in the Rural South
The benefits of adolescent vaccines are well known for preventing meningococcal infection and human papillomavirus (HPV)-related pre-cancerous lesions.
- Trial name
- INVEST (NCT04999267)
- Testing
- INVEST
- Where
- 2 sites in United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Duke University
HPV Vaccines
Effectiveness of SMS (Short Message Service) Text Messaging in Increasing Adherence to Gardasil
Human papillomavirus (HPV) is the most common sexually transmitted disease among adolescent females in the United States. Our primary objective is to determine if Short Message Service (SMS) text message reminders increase…
- Trial name
- CHAT (NCT01276184)
- Testing
- SMS Text Message
- Where
- 2 sites in United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
HPV16 Positive, Cervical Intraepithelial Neoplasia (CIN 2/3)
Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)
This study will test the efficacy and safety of different routes of administration of a DNA vaccine in patients with HPV16+ CIN2/3. Subjects will be enrolled in one of six treatment groups.
- Trial name
- NCT00988559
- Testing
- DNA vaccination, Gene gun vaccine, intramuscular vaccination
- Where
- 3 sites in United States
- Volunteers
- 132 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Health Personnel Attitude, Health Knowledge, Attitudes, Practice
Healthcare Provider Human Papillomavirus Education and Professional Skills Intervention
Healthcare providers (HCP) serving the El Paso U.S.-Mexico Border Region will be recruited to compare educational and professional skills interventions focused on the human papillomavirus (HPV).
- Trial name
- NCT05120869
- Testing
- Tailored HPV Education and Professional Skills Intervention Group, General HPV Education and Communication Skills Control Group
- Where
- 2 sites in United States
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- University of Texas, El Paso
Infections, Papillomavirus
Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents
Genital infections with oncogenic human papillomaviruses (HPV) are common in both men and women. The most important disease associated with oncogenic HPV infection is cervical cancer, currently the second leading cause of…
- Trial name
- NCT00534638
- Testing
- Cervarix, Engerix-B
- Where
- 6 sites in Finland
- Volunteers
- 34,412 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
PRD (Paediatric Rheumatological Disease), IBD (Inflammatory Bowel Disease)
HPV Vaccination in Special Risk Groups: 5 Year Follow-up
In 2007-2009 the investigators conducted a study to determine the immunogenicity response to HPV vaccine in special risk patients known to be at increased risk of abnormal cervical cytology.
- Trial name
- NCT01896986
- Where
- Australia
- Volunteers
- 37 people
- Sponsor
- Murdoch Childrens Research Institute
HPV Vaccination, Vaccine; Uptake
PREVENT HPV-Related Cancers - BootCamp Translation
This study will serve as one of the first to develop and test the effectiveness of strategies to promote HPV vaccination among diverse rural parents and caregivers of children ages 9-17 years in the Mountain West.
- Conditions
- HPV Vaccination, Vaccine; Uptake, Vaccination; Series Completion
- Trial name
- PREVENT (NCT06290206)
- Testing
- PREVENT - BCT
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Utah
Human Immunodeficiency Virus, Human Papillomavirus- 6, 11, 16, 18
A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults
Background: Human papilloma virus (HPV) is a common sexually transmitted disease. There are more than 100 different HPV types, and both males and females can get HPV infection.
- Conditions
- Human Immunodeficiency Virus, Human Papillomavirus- 6, 11, 16, 18, Adolescent, Papillomavirus Vaccines
- Trial name
- NCT00798265
- Testing
- Gardasil, Survey
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
HIV Positive, Anal Condylomata
The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata
The primary objective of this pilot study is to evaluate the effect of the HPV vaccine Gardasil on anal condylomata recurrence and persistence rates in HIV positive patients.
- Conditions
- HIV Positive, Anal Condylomata, Anal Warts, HIV Infections
- Trial name
- NCT00941889
- Testing
- Saline, Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Washington University School of Medicine
Cervical Cancer
An Intervention Study To Improve Human PapillomaVirus ( HPV) Immunization in Haitian and African American Girls
In the United States, Black women are more likely to die of cervical cancer than White women. In developing countries and globally, Haitian immigrant women are more likely to die of cervical cancer than any other women in the…
- Trial name
- HPV (NCT01254669)
- Testing
- BNI-brief Negotiated Interview
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Boston Medical Center
Vaccine Refusal
Optimizing HPV Vaccine Introduction in Shanghai, China
Within low, middle, and upper income countries, low vaccine coverage results from both obstacles to vaccine access and low confidence in vaccine programs.
- Trial name
- NCT03972813
- Testing
- Broadened information about cancers, Information about STDs, Information about infectious disease
- Where
- China
- Volunteers
- 1,021 people, healthy volunteers welcome
- Sponsor
- University of Michigan
HPV Vaccination Decision Quality
Educational Intervention to Improve HPV Vaccination Decision Quality
The purpose of this study is to evaluate an innovative approach to improving HPV vaccination among the Hispanic population. The objectives/aims of this HPV educational intervention project are: 1.
- Trial name
- NCT02797054
- Testing
- Tailored educational materials, Untailored educational materials, Usual care
- Where
- United States
- Volunteers
- 1,205 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
AIDS-Related Human Papillomavirus Infection, High Grade Cervical Squamous Intraepithelial Neoplasia
HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV
This randomized phase III trial studies how well human papillomavirus (HPV) vaccine therapy works in reducing high-grade cervical lesions in patients with human immunodeficiency virus (HIV) and HPV.
- Conditions
- AIDS-Related Human Papillomavirus Infection, High Grade Cervical Squamous Intraepithelial Neoplasia, HIV Infection
- Trial name
- COVENANT (NCT03284866)
- Testing
- Laboratory Biomarker Analysis, Recombinant Human Papillomavirus Nonavalent Vaccine, Saline
- Where
- 6 sites in Kenya, Malawi and 3 more
- Volunteers
- 535 people
- Sponsor
- AIDS Malignancy Consortium
Immunization, Efficacy
GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose
The investigators are evaluating whether 15-26 year old males and females need a 3rd dose of the human papillomavirus (HPV) vaccine, or whether 2 doses provide similar protection as 3 doses from the 9 types of HPV that it…
- Conditions
- Immunization, Efficacy, Human Papilloma Virus
- Trial name
- NCT03943875
- Testing
- 9-valent HPV vaccine, 2 dose efficacy, 9-valent HPV vaccine, 3 doses standard timing
- Where
- United States
- Volunteers
- 767 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
Immunization, Vaccination
The STOP-HPV Trial 1: Communication Intervention
Most adolescents who receive human papillomavirus (HPV) vaccine are vaccinated in pediatric practices, yet missed opportunities (MOs) for HPV vaccination occur often and lead to low HPV vaccination rates.
- Trial name
- STOP-HPV (NCT03599557)
- Testing
- STOP-HPV communication intervention
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles